BRIEF-Iambic Presents Updated Iam1363 Clinical Data At Esmo 2026, Showing Durable Responses With A Favorable Tolerability Profile In Heavily Pretreated Participants With Her2-Driven Cancers

2

Oct 26 (Reuters) – Iambic Therapeutics, Inc.: * IAMBIC PRESENTS UPDATED IAM1363 CLINICAL DATA AT ESMO 2026, SHOWING DURABLE RESPONSES WITH A FAVORABLE TOLERABILITY PROFILE IN HEAVILY PRETREATED

(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)